ESMO 2025 | Standardized screening criteria for cachexia in oncology trials

Lynn Gottmann • 19 Oct 2025

ESMO 2025

General

Lynn Gottmann, Medical University of Vienna, Vienna, Austria, emphasizes the need for unified screening criteria for cachexia in clinical trials to ensure consistency in inclusion criteria, allowing for longitudinal comparisons and the development of more effective interventions. Establishing standardized screening criteria is a crucial step towards creating a foundation for future therapies and improving treatment outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I think we need to take a step back first and find better unified screening criteria so clinical trials will use the same inclusion criteria so we have something to build on longitudinally to find better interventions or like fitting interventions okay and I think we first need to take a step back and to find better or unified screening criteria so clinical trials will use the same inclusion criteria and we will have something to build on for future therapies

This transcript is AI-generated...

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.